Drug Overdose Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Drug Overdose can occur with multiple symptoms including sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Treatment includes antidote and activated charcoal.

The Drug Overdose pipeline market report provides a comprehensive overview of the therapeutics under development for Drug Overdose, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects.

Drug Overdose Pipeline Drugs Market by Key Targets

In the Drug Overdose pipeline drug market, the key targets are Mu Type Opioid Receptor, Delta Type Opioid Receptor, Kappa Type Opioid Receptor, Cannabinoid Receptor 1, Free Radical, Acetylcholinesterase, Calcium Activated Potassium Channel Subunit Alpha 1, and Opioid Receptor.

Key Targets in the Drug Overdose Pipeline Drugs Market

Key Targets in the Drug Overdose Pipeline Drugs Market

For more target insights, download a free report sample

Key MoA in the Drug Overdose Pipeline Drugs Market

Mu Type Opioid Receptor Antagonist has the highest share in the Drug Overdose Pipeline Drugs Market. The other key mechanisms of action are Delta Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Antagonist, Cannabinoid Receptor 1 Antagonist, Free Radical Scavenger, Acetylcholinesterase Inhibitor, Calcium Activated Potassium Channel Subunit Alpha 1 Blocker, and Opioid Receptor Antagonist.

Drug Overdose Pipeline Drugs Market Analysis, by MoA

Drug Overdose Pipeline Drugs Market Analysis, by MoA

To get more insights on key MoA, download a free sample report

Drug Overdose Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Drug Overdose pipeline drug market are Nasal, Intravenous, Oral, Buccal, Subcutaneous, Parenteral, Intramuscular, and Transdermal. Nasal has the maximum number of pipeline products.

Drug Overdose Pipeline Drugs Market Analysis, by RoA

Drug Overdose Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Drug Overdose Pipeline Drugs Market

The key molecule type in the Drug Overdose pipeline drugs market are Small Molecule, Monoclonal Antibody, Antibody, Conjugate Vaccine, and Subunit Vaccine. Small molecule has the maximum number of pipeline products.

Drug Overdose Pipeline Drugs Market, by Major Companies

Drug Overdose Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Major Companies in the Drug Overdose Pipeline Drugs Market

Some of the major companies in the Drug Overdose pipeline drugs market are Emergent BioSolutions Inc, Opiant Pharmaceuticals Inc, Egetis Therapeutics AB, InterveXion Therapeutics LLC, Klaria Pharma Holding AB, Orexo AB, Vernalis R&D Ltd, Amphastar Pharmaceuticals Inc, Avior Bio Inc, and Clear Scientific LLC.

Drug Overdose Pipeline Drugs Market, by Major Companies

Drug Overdose Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Drug Overdose Pipeline Drugs Market Overview

Key Targets Mu Type Opioid Receptor, Delta Type Opioid Receptor, Kappa Type Opioid Receptor, Cannabinoid Receptor 1, Free Radical, Acetylcholinesterase, Calcium Activated Potassium Channel Subunit Alpha 1, and Opioid Receptor
Key Mechanisms of Action Mu Type Opioid Receptor Antagonist, Delta Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Antagonist, Cannabinoid Receptor 1 Antagonist, Free Radical Scavenger, Acetylcholinesterase Inhibitor, Calcium Activated Potassium Channel Subunit Alpha 1 Blocker, and Opioid Receptor Antagonist
Key Routes of Administration Nasal, Intravenous, Oral, Buccal, Subcutaneous, Parenteral, Intramuscular, and Transdermal
Key Molecule Types Small Molecule, Monoclonal Antibody, Antibody, Conjugate Vaccine, and Subunit Vaccine
Major Companies Emergent BioSolutions Inc, Opiant Pharmaceuticals Inc, Egetis Therapeutics AB, InterveXion Therapeutics LLC, Klaria Pharma Holding AB, Orexo AB, Vernalis R&D Ltd, Amphastar Pharmaceuticals Inc, Avior Bio Inc, and Clear Scientific LLC

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose
  • The pipeline guide reviews pipeline therapeutics for Drug Overdose by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Overdose therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Overdose therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Drug Overdose

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Overdose
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Overdose pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Amphastar Pharmaceuticals Inc
Avior Bio Inc
Clear Scientific LLC
Crossject SA
Egetis Therapeutics AB
Emergent BioSolutions Inc
Enalare Therapeutics Inc
Fab’entech SA
Hepione Therapeutics Inc
Icure Pharmaceutical Inc
InterveXion Therapeutics LLC
Klaria Pharma Holding AB
Mucodel Pharma LLC
Nasus Pharma Ltd
Opiant Pharmaceuticals Inc
Orexo AB
ResQ Pharma Inc
Sparian Biosciences Inc
Vallon Pharmaceuticals Inc
Vernalis R&D Ltd
Worphmed Srl

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Drug Overdose – Overview

Drug Overdose – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Drug Overdose – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Overdose – Companies Involved in Therapeutics Development

Amphastar Pharmaceuticals Inc

Avior Bio Inc

Clear Scientific LLC

Crossject SA

Egetis Therapeutics AB

Emergent BioSolutions Inc

Enalare Therapeutics Inc

Fab’entech SA

Hepione Therapeutics Inc

Icure Pharmaceutical Inc

InterveXion Therapeutics LLC

Klaria Pharma Holding AB

Mucodel Pharma LLC

Nasus Pharma Ltd

Opiant Pharmaceuticals Inc

Orexo AB

ResQ Pharma Inc

Sparian Biosciences Inc

Vallon Pharmaceuticals Inc

Vernalis R&D Ltd

Worphmed Srl

Drug Overdose – Drug Profiles

Antibody for Drug Overdose, Opioid Addiction and Poisoning – Drug Profile

Product Description

Mechanism Of Action

drinabant – Drug Profile

Product Description

Mechanism Of Action

History of Events

ENA-001 – Drug Profile

Product Description

Mechanism Of Action

IXTf-250 – Drug Profile

Product Description

Mechanism Of Action

IXTM-200 – Drug Profile

Product Description

Mechanism Of Action

History of Events

melatonin – Drug Profile

Product Description

Mechanism Of Action

History of Events

nalmefene – Drug Profile

Product Description

Mechanism Of Action

History of Events

nalmefene – Drug Profile

Product Description

Mechanism Of Action

History of Events

nalmefene – Drug Profile

Product Description

Mechanism Of Action

naloxone – Drug Profile

Product Description

Mechanism Of Action

History of Events

naloxone – Drug Profile

Product Description

Mechanism Of Action

History of Events

naloxone – Drug Profile

Product Description

Mechanism Of Action

naloxone – Drug Profile

Product Description

Mechanism Of Action

History of Events

naloxone – Drug Profile

Product Description

Mechanism Of Action

History of Events

naloxone hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

naloxone hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

naloxone hydrochloride 1 – Drug Profile

Product Description

Mechanism Of Action

naloxone. – Drug Profile

Product Description

Mechanism Of Action

History of Events

OPNT-006 – Drug Profile

Product Description

Mechanism Of Action

History of Events

physostigmine – Drug Profile

Product Description

Mechanism Of Action

PP-100 – Drug Profile

Product Description

Mechanism Of Action

SBS-371 – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Acute Opioid Overdosage – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Drug Overdose and Drug Toxicity – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Alzheimer’s Disease and Drug Overdose – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Substance Abuse and Drug Overdose – Drug Profile

Product Description

Mechanism Of Action

V-24343 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Vaccine for Drug Overdose – Drug Profile

Product Description

Mechanism Of Action

Vaccine for Drug Overdose – Drug Profile

Product Description

Mechanism Of Action

Drug Overdose – Dormant Projects

Drug Overdose – Discontinued Products

Drug Overdose – Product Development Milestones

Featured News & Press Releases

Apr 01, 2022: Anebulo Pharmaceuticals doses more than half of the subjects in part A of a phase 2 clinical trial and provides guidance on IND submission

Feb 08, 2022: Teva agrees to pay $225m to settle opioid claims in Texas

Jan 03, 2022: Anebulo Pharmaceuticals announces initiation of phase 2 clinical study evaluating ANEB-001 for the treatment of acute cannabinoid intoxication

Dec 20, 2021: Klaria Pharma initiates clinical study with Naloxon Alginate Film

Dec 02, 2021: Klaria Pharma receives approval to initiate clinical Phase 1 trial of Naloxone Alginate Film

Nov 16, 2021: Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124

Oct 22, 2021: Klaria Pharma announces approval by the United Stated Patent and Trademark Office of a new patent application covering naloxone alginate film

Oct 13, 2021: Anebulo Pharmaceuticals announces issuance of U.S. patent covering use of ANEB-001 for the treatment of acute Cannabinoid overdose

Sep 13, 2021: Anebulo Pharmaceuticals announces completion of manufacturing of ANEB-001 capsules for upcoming phase 2 clinical trial

Jul 16, 2021: Orexo’s flagship pharmaceutical pipeline asset OX124 enters pivotal trial

Apr 13, 2021: Nasus Pharma announces positive results in pivotal trial of FMXIN001 Naloxone powder-based nasal spray for the treatment of opioid overdose

Feb 08, 2021: Opiant Pharmaceuticals announces first patient dosed in confirmatory pharmacokinetic study assessing OPNT003, nasal nalmefene, for the treatment of opioid overdose

Feb 05, 2021: Klaria announces patent approval in Europe of a new product patent covering Naloxone Alginate Film

Jan 29, 2021: Orexo expects FDA filing of OX124 mid 2022

Jan 27, 2021: Orexo strengthens IP rights for overdose rescue drug OX124

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Drug Overdose, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Drug Overdose – Pipeline by Amphastar Pharmaceuticals Inc, 2022

Drug Overdose – Pipeline by Avior Bio Inc, 2022

Drug Overdose – Pipeline by Clear Scientific LLC, 2022

Drug Overdose – Pipeline by Crossject SA, 2022

Drug Overdose – Pipeline by Egetis Therapeutics AB, 2022

Drug Overdose – Pipeline by Emergent BioSolutions Inc, 2022

Drug Overdose – Pipeline by Enalare Therapeutics Inc, 2022

Drug Overdose – Pipeline by Fab’entech SA, 2022

Drug Overdose – Pipeline by Hepione Therapeutics Inc, 2022

Drug Overdose – Pipeline by Icure Pharmaceutical Inc, 2022

Drug Overdose – Pipeline by InterveXion Therapeutics LLC, 2022

Drug Overdose – Pipeline by Klaria Pharma Holding AB, 2022

Drug Overdose – Pipeline by Mucodel Pharma LLC, 2022

Drug Overdose – Pipeline by Nasus Pharma Ltd, 2022

Drug Overdose – Pipeline by Opiant Pharmaceuticals Inc, 2022

Drug Overdose – Pipeline by Orexo AB, 2022

Drug Overdose – Pipeline by ResQ Pharma Inc, 2022

Drug Overdose – Pipeline by Sparian Biosciences Inc, 2022

Drug Overdose – Pipeline by Vallon Pharmaceuticals Inc, 2022

Drug Overdose – Pipeline by Vernalis R&D Ltd, 2022

Drug Overdose – Pipeline by Worphmed Srl, 2022

Drug Overdose – Dormant Projects, 2022

Drug Overdose – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Drug Overdose, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Drug Overdose Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Drug Overdose Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Drug Overdose Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.